Drug Trial Radar · NCT04926116
A Study of AK3280 in Chinese Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jun 9, 2021
Primary completion
Sep 28, 2021
Study completion Sep 28, 2021
Sponsor
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, single-center, phase I study to evaluate the safety, tolerability, and pharmacokinetics of AK3280 in healthy Chinese subjects.
Conditions
- Healthy
Interventions
AK3280Drug
Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
PlaceboDrug
Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects with Adverse Events (AEs)Time frame: From baseline up to approximately 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.